Explore Business Standard
Pharma
As many as 300 products, including that of engineering goods, pharma, agri, and chemicals, hold huge potential for Indian exporters to push their shipments to Russia as the two countries target USD 100 billion trade by 2030, an official said. At present, India's exports of these goods to Russia stood at USD 1.7 billion, as against Russia's USD 37.4 billion in imports. "This stark disparity demonstrates the substantial complementary export space India can target," the official said, adding increasing exports will also help India bridge its trade deficit with Russia, which stood at USD 59 billion. These high-potential products have been selected by the commerce ministry by analysing complementary basket of products -- mapping India's supply visa-a-vis Russia's demand across key sectors, the official added. The most promising areas mirror India's rising global strengths are engineering goods, pharmaceuticals, chemicals and agriculture, all of which correspond to substantial unmet dema
Amid growing demand for stricter compliance with safety and quality control norms for medical products, the Centre is framing a law to strengthen the legal framework for drug quality testing and market surveillance, along with regulation of medical devices and cosmetics. One of the major reasons behind the drafting of the law is the repeated complaints and concerns flagged by health regulators across the globe, including the WHO, over serious quality lapses by Indian drug manufacturers. The draft of the 'Drugs, Medical Devices and Cosmetics Act 2025', which the government aims to introduce in the upcoming Winter session of Parliament, was presented by Drugs Controller General of India (DCGI) Dr Rajeev Raghuvanshi at a high-level meeting of the Union health ministry held on Tuesday, the sources said. The meeting was chaired by Union Health Minister J P Nadda. During the meeting, senior officials from the Drugs Controller General of India (DCGI) and the Central Drugs Standard Control
The Drugs Controller General of India (DCGI) has urged all drug controllers of the states and Union Territories to ensure testing of raw materials and finished formulations of pharmaceutical products before releasing them in the market in the wake of children's deaths allegedly due to the consumption of contaminated cough syrup in Madhya Pradesh and Rajasthan. Five children from Madhya Pradesh are in a critical condition, while 20 have died due to kidney infections caused by the consumption of the "contaminated" cough syrup, containing Diethylene Glycol (DEG) and Ethylene Glycol (EG). Besides, at least three children have allegedly died in Rajasthan after consuming cough syrup in different districts of the state. In an advisory, the DCGI said that during recent inspections at manufacturing facilities and in the investigations of the drugs declared as 'Not of Standard Quality', it was found that several manufacturers are not testing each batch of excipients and active ingredients for
Drug firm Lupin on Wednesday said it will set up a new manufacturing facility in Coral Springs, Florida, entailing an investment of USD 250 million. With a projected cumulative investment of USD 250 million, including research & development, infrastructure and capital expenditures over a five-year period, the new site will have the capacity to accommodate the production of more than 25 critical respiratory medicines, the Mumbai-based drug maker said in a regulatory filing. The Florida-based plant would produce products like albuterol inhalers for children with asthma, it added. By strengthening domestic manufacturing and enhancing supply chain diversification, this critical project will enhance medicine security and strengthen the company's position as a global respiratory leader, it said. Locally, the infrastructure will generate over 200 new long-term, skilled jobs by 2030 in Broward County. "The expansion of Lupin's footprint in Coral Springs is a core part of our growth ...
The Kerala government on Tuesday banned the distribution of medicines manufactured by Tamil Nadu-based Sresan Pharmaceuticals. The decision follows steps by the Tamil Nadu Drugs Controller to cancel the company's licence, state Health Minister Veena George said. Sales of Respifresh TR, manufactured by a Gujarat-based firm, were also stopped immediately after the drug was found to be substandard, the minister said in a statement. There are five distributors in the state supplying this medicine, and they have been instructed to stop distribution, George said. Strict action will be taken against those selling this medicine. Those in possession of this drug are requested not to use it. These medicines are not distributed through government hospitals. She added that strict action would be initiated against establishments that provide medicines to children under the age of 12 without a prescription from an authorised doctor. The ban comes after reports that 14 children in Chhindwara, M